Studies related to Memory and Ashwagandha

Randomized Placebo-controlled Adjunctive Study Of An Extract Of Withania Somnifera For Cognitive Dysfunction In Bipolar Disorder

Effect Increase
Values Auditory Digit Span. Least squares mean + standard error. (change from baseline). Backward: Placebo: 0.17 (0.18). Intervention: 0.73 (0.19). Forward: Placebo: 0.39 (0.16). Intervention: 0.13 (0.18).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 60 subjects with bipolar disorder took an ashwagandha extract or placebo for 8 weeks. The subjects who took ashwagandha received 250 mg/d (standardized to a minimum of 8% withanolides and a maximum of 2% Withaferin A) for the first week, and 500 mg for the rest of the study, however, if the participants suspected adverse effects of ashwagandha, they were allowed to reduce their dose to 250 mg/d, which was the case with 3.

The primary outcome was working memory as evaluated by an auditory 8 Digit-Span test. Compared with placebo, the ashwagandha group saw a small, statistically significant improvement in the span backward portion, but not for span forward.

The participants also performed the flanker test and the results favored the ashwagandha group but were only statistically significant for the neutral condition. Results for tests of executive function and processing speed were ambiguous and not statistically significant. The researchers also evaluated affective symptoms and possibly found reductions in depression and mania, but not anxiety, though statistical tests weren't performed for these. The only adverse event that seemed to be higher in the ashwagandha group was diarrhea in 5 participants compared with 1 in the placebo group.

Efficacy And Safety Of Ashwagandha (Withania Somnifera (L.) Dunal) Root Extract In Improving Memory And Cognitive Functions

Effect Increase
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 50
Gender Both Genders
Age Range 30-44, 45-64, 65+
Body Types Obese, Overweight, Average
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 50 subjects with memory impairment, early dementia, or a low score on a general cognitive function test took either placebo or 600 mg of an ashwagandha root extract for 8 weeks.

The primary outcome was considered to be performance on various cognitive tests, including memory, visuospatial processing, executive function, and attention. At the end of 8 weeks, participants taking ashwagandha saw statistically significant improvements compared with the placebo group in most memory tests, executive function, and attention, though not visuospatial processing.

A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ASHWAGANDHA ON GENERALIZED ANXIETY DISORDER
Effect Increase
Values Hamilton’s Anxiety Rating Scale. Mean score. Placebo: before 1.68, after 1.4. Intervention: before 2.25, after 0.51
Trial Design randomized
Trial Length 16months
Number of Subjects 86
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled study, 86 patients with Generalized Anxiety Disorder were assigned to take either placebo or 12 g of ashwagandha sugar granules (unclear dose of ashwagandha and its chemicals) daily for 60 days. The primary and only outcome was the symptoms on the Hamilton Anxiety Rating Scale. Compared with the placebo group, the ashwaganda group saw a statistically significant improvement in "anxious mood" and "tension", while the differences weren't statistically significant for the other symptoms. However, the reduction in every symptom was greater for the ashwagandha group than the placebo group. 58.13% of patients in the ashwagandha group were evaluated as seeing a moderate improvement, 39.53% saw a mild improvement, and 2.32% were unchanged. In the placebo group, this was 0, 81.39, and 18.6%, respectively.